Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…
Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…
EULAR & ACR COVID-19 Recommendations: How to Manage Patients During the COVID-19 Pandemic
ACR & EULAR recommendations for the treatment of patients with rheumatic illness during the COVID-19 pandemic are explored…
New Insights into the Management of Giant Cell Arteritis
A systematic literature review identified novel evidence on the treatment and management of GCA that was incorporated into the most recent EULAR recommendations on the management of large vessel vasculitis. Investigators confirmed the efficacy of prompt initiation of glucocorticoids and found fast-track approaches to diagnosis lowered the risk of ischemic complications…
A Report from 2 ACR/EULAR Exchange Participants
Since 1998, the ACR/European League Against Rheumatism (EULAR) Exchange Program has supported junior academic rheumatologists, rheumatology professionals and health professionals in rheumatology in traveling from Europe to the U.S., and vice versa, to exchange clinical and research skills, expertise and knowledge. The program is designed to recognize outstanding early career faculty in rheumatology research, so…
New Consensus Recommendations Guide Sjögren’s Syndrome Management
NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies. Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers)….
Move Along: Insights Into Gastrointestinal Involvement in Systemic Sclerosis
For patients with gastrointestinal (GI) manifestations of scleroderma, the effect on quality of life & longevity can be dramatic. But advances are being made in the diagnosis & treatment of these patients…
Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients
MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European…
Researchers Seek the Best Methods to Maintain Remission in Vasculitis
MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…
More Than Skin Deep: Insights into Clinical Challenges in Psoriatic Arthritis
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 16
- Next Page »